Two recent tweets from Dr. Robert Malone shed light on two matters that have puzzled some.
Question: Why do you people resist experimental gene therapy injections? Malone indicated yesterday that resistance appears to arise from information. So this tweet explains that:
This is key. The most hesitant are the most educated. https://t.co/foi5At4kdJ— Robert W Malone, MD (@RWMaloneMD) August 8, 2021
Question: Why are we hearing so little about adverse effects from the gene therapy injections? Especially, for example, from some very heavily injected countries? It seems the Pfizer--for one--enters into contractual agreements with governments that protect Pfizer not only from liability but even from adverse publicity:
This is key to understanding "what the heck is going on". Apparently in Israel, I am told by Israeli scientist, the agreement between Pfizer and the government is that no adverse events from the vax are to be disclosed for a minimum of 10 years. https://t.co/aLcLUpVQHP— Robert W Malone, MD (@RWMaloneMD) August 8, 2021
Information security expert on revealed Pfizer agreements: ‘There’s good reason Pfizer fought to hide the details of these contracts’
Excerpts from the contract boilerplate--it may differ from country to country in the details, but the basics remain pretty much the same. While the term "adverse effects" doesn't appear below, I think it's probably reasonable to assume that the Israeli scientist who spoke with Malone understands the thrust of the confidentiality agreement.
‘Purchaser acknowledges…the long-term effects and efficacy of the Vaccine are not currently known and that there may be adverse effects of the Vaccine that are not currently known.
“‘Purchaser hereby agrees to indemnify, DEFEND AND HOLD HARMLESS Pfizer, BioNTech (and) their Affiliates…from and against any and all suits, claims, actions, demands, losses, damages, liabilities, settlements, penalties, fines, costs and expenses…’
“Confidentiality, part 1: ‘Each Recipient shall safeguard the confidential and proprietary nature of the Disclosing Party’s Confidential Information with at least the same degree of care as it holds its own confidential or proprietary information of like kind’:
“Confidentiality, part 2: ‘Recipient shall disclose Confidential Information only to such of its Representatives who have a need to know such Confidential Information to fulfill its obligations under this Agreement’:
“‘The provisions of this Section 10 (Confidential Information) shall survive the termination or expiration of the this Agreement for a period of ten (10) years’: